News
Geron leaps as ODAC backs its MDS drug imetelstat
Shares in Geron have almost doubled in after-hours trading after the FDA’s Oncological Drugs Advisory Committee (ODAC) voted by 12 to 2 in favour of its imetelstat therapy
